多模式抗血管治疗的纳米颗粒:双重药物释放、光热和光动力治疗
Nanoparticles for Multimodal Antivascular Therapeutics: Dual Drug Release, Photothermal and Photodynamic Therapy
摘要:
纳米颗粒对靶向癌细胞的不良递送阻碍了它们在临床环境中的成功。在这项工作中,已经选择了一种可用于循环纳米颗粒的替代靶点,以消除纳米颗粒在组织中渗透的需要:肿瘤血管。本文提出了一种能够共递送两种抗血管药物(一种抗血管生成药物和一种血管破坏剂)的肿瘤内皮靶向纳米颗粒(采用含RGD的肽)。此外,该纳米器件在被近红外线激活时呈现出两种额外的抗血管能力:引发局部高热(通过系统中的金纳米棒)和产生有毒的活性氧物质(通过光敏剂的存在)。RGD靶向显示出增加HUVEC细胞的摄取,并且虽然纳米颗粒显示出对这些细胞没有毒性,但在近红外辐射后,它们几乎完全被杀死。然后在卵外纤维肉瘤异种移植物模型中评估所有四种治疗方式的组合,其显示当存在纳米颗粒时冲洗异种移植物的血管数量显著减少,以及在照射时破坏现有血管。这些结果表明,在单一纳米载体中组合不同的抗血管治疗策略似乎是有希望的,并且应该在未来进一步探索。
英文摘要:
The poor delivery of nanoparticles to target cancer cells hinders their success in the clinical setting. In this work, an alternative target readily available for circulating nanoparticles has been selected to eliminate the need for nanoparticle penetration in the tissue: the tumor blood vessels. A tumor endothelium-targeted nanoparticle (employing an RGD-containing peptide) capable of co-delivering two anti-vascular drugs (one anti-angiogenic drug and one vascular disruption agent) is here presented. Furthermore, the nanodevice presents two additional anti-vascular capabilities upon activation by Near-Infrared light: provoking local hyperthermia (by gold nanorods in the system) and generating toxic reactive oxygen species (by the presence of a photosensitizer). RGD-targeting is shown to increase uptake by HUVEC cells, and while the nanoparticles are shown not to be toxic for these cells, upon Near-Infrared irradiation their almost complete killing is achieved. The combination of all four therapeutic modalities is then evaluated in an ex ovo fibrosarcoma xenograft model, which shows a significant reduction in the number of blood vessels irrigating the xenografts when the nanoparticles are present, as well as the destruction of the existing blood vessels upon irradiation. These results suggest that the combination of different anti-vascular therapeutic strategies in a single nanocarrier appears promising and should be further explored in the future.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。